MA63589B1 - Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle - Google Patents
Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyleInfo
- Publication number
- MA63589B1 MA63589B1 MA63589A MA63589A MA63589B1 MA 63589 B1 MA63589 B1 MA 63589B1 MA 63589 A MA63589 A MA 63589A MA 63589 A MA63589 A MA 63589A MA 63589 B1 MA63589 B1 MA 63589B1
- Authority
- MA
- Morocco
- Prior art keywords
- triazolyl
- methyl substituted
- substituted alpha
- galactopyranoside
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La présente invention concerne des inhibiteurs de la galectine-3 représentés par la formule (I) et des sels pharmaceutiquement acceptables de ceux-ci, des compositions pharmaceutiques comprenant de tels composés, et leurs utilisations médicales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021055348 | 2021-03-03 | ||
| EP22708569.3A EP4301748B1 (fr) | 2021-03-03 | 2022-03-02 | Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle |
| PCT/EP2022/055224 WO2022184755A1 (fr) | 2021-03-03 | 2022-03-02 | Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA63589B1 true MA63589B1 (fr) | 2025-07-31 |
Family
ID=80682779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA63589A MA63589B1 (fr) | 2021-03-03 | 2022-03-02 | Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20240109930A1 (fr) |
| EP (1) | EP4301748B1 (fr) |
| JP (1) | JP7771205B2 (fr) |
| KR (1) | KR20230154221A (fr) |
| CN (1) | CN116888113A (fr) |
| AU (1) | AU2022228660A1 (fr) |
| BR (1) | BR112023017624A2 (fr) |
| CA (1) | CA3209917A1 (fr) |
| CL (1) | CL2023002578A1 (fr) |
| ES (1) | ES3033422T3 (fr) |
| HR (1) | HRP20250833T1 (fr) |
| HU (1) | HUE072194T2 (fr) |
| IL (1) | IL305581A (fr) |
| MA (1) | MA63589B1 (fr) |
| MX (1) | MX2023010241A (fr) |
| PL (1) | PL4301748T3 (fr) |
| RS (1) | RS67032B1 (fr) |
| TW (1) | TWI905393B (fr) |
| UA (1) | UA130562C2 (fr) |
| WO (1) | WO2022184755A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| WO2022073969A1 (fr) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Dérivés spiro d'alpha-d-galactopyranosides |
| US12291520B2 (en) | 2020-11-02 | 2025-05-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives |
| JP7844491B2 (ja) | 2021-02-09 | 2026-04-13 | イドルシア・ファーマシューティカルズ・リミテッド | ヒドロキシヘテロシクロアルカン－カルバモイル誘導体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| KR102231732B1 (ko) | 2012-10-10 | 2021-03-23 | 갈렉틴 테라퓨틱스, 인크. | 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물 |
| IN2015DN02573A (fr) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| EP2919802A4 (fr) | 2012-11-15 | 2016-09-14 | Univ Tufts | Méthodes, compositions et kits de traitement, de modulation ou de prévention de l'angiogenèse ou de la fibrose oculaire chez un sujet utilisant un inhibiteur de galectine |
| CA2970062C (fr) | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Inhibiteurs alpha-d-galactoside de galectines |
| ES2734713T3 (es) | 2015-07-06 | 2019-12-11 | Gilead Sciences Inc | Moduladores Cot y métodos de utilización de los mismos |
| CA3062649A1 (fr) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Composes pour le traitement de troubles de la resistance systemique a l'insuline et leur utilisation |
| KR102626669B1 (ko) | 2017-05-12 | 2024-01-17 | 갈랙틴 사이언시즈, 엘엘씨 | 질환의 예방 및 치료를 위한 화합물 및 이의 용도 |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2019075045A1 (fr) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibiteurs à petites molécules de galectine-3 |
| JP2021501180A (ja) | 2017-10-31 | 2021-01-14 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用 |
| US11447517B2 (en) | 2018-11-21 | 2022-09-20 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| US12269819B2 (en) | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP7674276B2 (ja) | 2019-07-03 | 2025-05-09 | ガレクト バイオテック エービー | ガレクチンの新規なガラクトシド阻害剤 |
| CA3143078A1 (fr) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Nouvel inhibiteur galactoside de galectines |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
-
2022
- 2022-03-02 WO PCT/EP2022/055224 patent/WO2022184755A1/fr not_active Ceased
- 2022-03-02 KR KR1020237033375A patent/KR20230154221A/ko active Pending
- 2022-03-02 HR HRP20250833TT patent/HRP20250833T1/hr unknown
- 2022-03-02 MX MX2023010241A patent/MX2023010241A/es unknown
- 2022-03-02 CA CA3209917A patent/CA3209917A1/fr active Pending
- 2022-03-02 UA UAA202304634A patent/UA130562C2/uk unknown
- 2022-03-02 IL IL305581A patent/IL305581A/en unknown
- 2022-03-02 EP EP22708569.3A patent/EP4301748B1/fr active Active
- 2022-03-02 CN CN202280017484.3A patent/CN116888113A/zh active Pending
- 2022-03-02 JP JP2023552539A patent/JP7771205B2/ja active Active
- 2022-03-02 PL PL22708569.3T patent/PL4301748T3/pl unknown
- 2022-03-02 BR BR112023017624A patent/BR112023017624A2/pt unknown
- 2022-03-02 TW TW111107565A patent/TWI905393B/zh active
- 2022-03-02 AU AU2022228660A patent/AU2022228660A1/en active Pending
- 2022-03-02 US US18/548,833 patent/US20240109930A1/en active Pending
- 2022-03-02 ES ES22708569T patent/ES3033422T3/es active Active
- 2022-03-02 MA MA63589A patent/MA63589B1/fr unknown
- 2022-03-02 RS RS20250732A patent/RS67032B1/sr unknown
- 2022-03-02 HU HUE22708569A patent/HUE072194T2/hu unknown
-
2023
- 2023-08-31 CL CL2023002578A patent/CL2023002578A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023017624A2 (pt) | 2023-10-10 |
| CL2023002578A1 (es) | 2024-03-22 |
| RS67032B1 (sr) | 2025-08-29 |
| HUE072194T2 (hu) | 2025-10-28 |
| US20240109930A1 (en) | 2024-04-04 |
| JP7771205B2 (ja) | 2025-11-17 |
| MX2023010241A (es) | 2023-09-12 |
| TWI905393B (zh) | 2025-11-21 |
| UA130562C2 (uk) | 2026-03-18 |
| IL305581A (en) | 2023-10-01 |
| AU2022228660A1 (en) | 2023-10-19 |
| EP4301748C0 (fr) | 2025-05-07 |
| JP2024509421A (ja) | 2024-03-01 |
| WO2022184755A1 (fr) | 2022-09-09 |
| EP4301748A1 (fr) | 2024-01-10 |
| HRP20250833T1 (hr) | 2025-09-12 |
| CA3209917A1 (fr) | 2022-09-09 |
| EP4301748B1 (fr) | 2025-05-07 |
| CN116888113A (zh) | 2023-10-13 |
| TW202300146A (zh) | 2023-01-01 |
| KR20230154221A (ko) | 2023-11-07 |
| ES3033422T3 (en) | 2025-08-04 |
| PL4301748T3 (pl) | 2025-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA58498B1 (fr) | Agonistes hétérocycliques de glp-1 | |
| MA56883B1 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| MX2023001379A (es) | Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a. | |
| MA52360B1 (fr) | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines | |
| CL2023001461A1 (es) | Inhibidores de prmt5 novedosos | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| MA29926B1 (fr) | Derives de pyrazine | |
| JOP20230138A1 (ar) | مثبطات prmt5 | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| MA54608B1 (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA55046B1 (fr) | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 | |
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MX2022015886A (es) | Derivados de amidopirimidona. | |
| MA30403B1 (fr) | Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA34819B1 (fr) | Dérivés bicyclo[3.2.1]octylamide et leurs utilisations | |
| MA56526B1 (fr) | Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| MA57000B1 (fr) | Dérivés d'alpha-d-galactopyranoside | |
| MA28270A1 (fr) | Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2 | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA31080B1 (fr) | Dérivés cyclisés en tant qu'inhibiteurs d'eg-5. | |
| MA30959B1 (fr) | Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp |